Trials / Terminated
TerminatedNCT00281294
A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- PDL BioPharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of fontolizumab in subjects with active rheumatoid arthritis as determined by a 50% improvement of an American College of Rheumatology criteria (ACR50) response at Week 14 (Stage A of study).
Detailed description
To evaluate the efficacy of fontolizumab in subjects with active rheumatoid arthritis as determined by a 50% improvement of an American College of Rheumatology criteria (ACR50) response at Week 14 (Stage A of study). Stage B of this trial is Double blind.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fontolizumab |
Timeline
- Start date
- 2005-12-01
- Completion
- 2006-12-01
- First posted
- 2006-01-24
- Last updated
- 2008-08-05
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00281294. Inclusion in this directory is not an endorsement.